Overview

The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning Dosing

Status:
Completed

Trial end date:
2004-08-01

Target enrollment:

Participant gender:

Summary

To compare the percentage of subjects with a glucose measurement < than or = to 56 mg/dL at any point of the 8-point glucose profiles during 3 consecutive days before vs. 3 consecutive days after switching insulin glargine dosing time from bedtime to morning and vs. 3 consecutive days after switching back to bedtime dosing of insulin glargine.

Phase:

Phase 4

Details

Lead Sponsor:

Sanofi

Treatments:

Insulin
Insulin Glargine
Insulin, Globin Zinc